"If he didn't expect success, he wouldn't be talking about commercialization and wouldn't waste good money on stockpiling a supply for it. IMO of course."
Not necessarily true. As anybody in the drug development business knows, you don't know what the data looks like until you actually have the data and it's analyzed. Missling is smart to stockpile A2-73 because if the trials are successful, he doesn't want there to be a delay while sufficient quantities are made.
And if the data are bad, the whole thing goes down the drain anyway.